These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38497758)

  • 41. On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse.
    Reverter-Branchat G; Segura J; Pozo OJ
    Drug Test Anal; 2021 Mar; 13(3):510-522. PubMed ID: 33197153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The fight against doping: today and tomorrow].
    Rieu M
    Bull Acad Natl Med; 2004; 188(6):955-71; discussion 972. PubMed ID: 15651425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Altitude exposure in sports: the Athlete Biological Passport standpoint.
    Sanchis-Gomar F; Pareja-Galeano H; Brioche T; Martinez-Bello V; Lippi G
    Drug Test Anal; 2014 Mar; 6(3):190-3. PubMed ID: 24115763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Football for life versus antidoping for the masses: ethical antidoping issues and solutions based on the extenuating experiences of an elite footballer competing while undergoing treatment for metastatic testicular cancer.
    Weiler R; Tombides D; Urwin J; Clarke J; Verroken M
    Br J Sports Med; 2014 May; 48(10):814-6. PubMed ID: 24668050
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sports drug testing using complementary matrices: Advantages and limitations.
    Thevis M; Geyer H; Tretzel L; Schänzer W
    J Pharm Biomed Anal; 2016 Oct; 130():220-230. PubMed ID: 27040951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The potential role of oral fluid in antidoping testing.
    Anizan S; Huestis MA
    Clin Chem; 2014 Feb; 60(2):307-22. PubMed ID: 24153253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport.
    Schumacher YO; Saugy M; Pottgiesser T; Robinson N
    Drug Test Anal; 2012 Nov; 4(11):846-53. PubMed ID: 22374784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating microRNA as a biomarker of human growth hormone administration to patients.
    Kelly BN; Haverstick DM; Lee JK; Thorner MO; Vance ML; Xin W; Bruns DE
    Drug Test Anal; 2014 Mar; 6(3):234-8. PubMed ID: 23495241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood doping and its detection.
    Jelkmann W; Lundby C
    Blood; 2011 Sep; 118(9):2395-404. PubMed ID: 21652677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Athlete Biological Passport from the perspective of an anti-doping organization.
    Zorzoli M
    Clin Chem Lab Med; 2011 Sep; 49(9):1423-5. PubMed ID: 21726163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of Stimulated Erythropoiesis by the RNA-Based 5'-Aminolevulinate Synthase 2 Biomarker in Dried Blood Spot Samples.
    Salamin O; Gottardo E; Schobinger C; Reverter-Branchat G; Segura J; Saugy M; Kuuranne T; Tissot JD; Favrat B; Leuenberger N
    Clin Chem; 2019 Dec; 65(12):1563-1571. PubMed ID: 31570629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Faster, higher, stronger: knowledge about old and new doping substances].
    Pieters T; de Hon O
    Ned Tijdschr Geneeskd; 2013; 157(28):A6450. PubMed ID: 23841931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel antidoping and medical care delivery model at the 2nd Summer Youth Olympic Games (2014), Nanjing China.
    Mountjoy M; Akef N; Budgett R; Greinig S; Li G; Manikavasagam J; Soligard T; Haiming X; Yang X
    Br J Sports Med; 2015 Jul; 49(13):887-92. PubMed ID: 25833900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015.
    Dvorak J; Baume N; Botré F; Broséus J; Budgett R; Frey WO; Geyer H; Harcourt PR; Ho D; Howman D; Isola V; Lundby C; Marclay F; Peytavin A; Pipe A; Pitsiladis YP; Reichel C; Robinson N; Rodchenkov G; Saugy M; Sayegh S; Segura J; Thevis M; Vernec A; Viret M; Vouillamoz M; Zorzoli M
    Br J Sports Med; 2014 May; 48(10):801-6. PubMed ID: 24764550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doping control from a global and national perspective.
    Fraser AD
    Ther Drug Monit; 2004 Apr; 26(2):171-4. PubMed ID: 15228160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of RNA-based 5'-aminolevulinate synthase 2 biomarkers in dried blood spots to detect recombinant human erythropoietin microdoses.
    Loria F; Cox HD; Voss SC; Rocca A; Miller GD; Townsend N; Georgakopoulos C; Eichner D; Kuuranne T; Leuenberger N
    Drug Test Anal; 2022 May; 14(5):826-832. PubMed ID: 34216436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. International Sports Federation's fight to protect the clean athlete: are we doing enough in the fight against doping?
    Mountjoy M; Miller S; Vallini M; Foster J; Carr J
    Br J Sports Med; 2017 Sep; 51(17):1241-1242. PubMed ID: 28659359
    [No Abstract]   [Full Text] [Related]  

  • 59. Brazilian antidoping public policy.
    Almeida CB; Rodrigues DN
    Subst Use Misuse; 2014 Jul; 49(9):1146-51. PubMed ID: 24799072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A role for metabolomics in the antidoping toolbox?
    Narduzzi L; Dervilly G; Audran M; Le Bizec B; Buisson C
    Drug Test Anal; 2020 Jun; 12(6):677-690. PubMed ID: 32144900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.